March 14 (Reuters) - Biotechnology company Supergen Inc. (SUPG.O: Quote, Profile , Research) said it expects loss from operations in 2007 of $500,000 to $1 million and revenue of about $32 million.
In a conference call, the company said it sees research and development expenses of between $21 million and $22.5 million in 2007. Supergen said it sees non-cash stock option expense of $3.5 million to $4 million in the year.
Analysts on average expect revenue of $27.9 million, according to Reuters Estimates. (Reporting by Neha Pathania in Bangalore)
11.2M Deferred gain on sale of Nipent 10.3M Acceleration clause 3.25M Nipent EU sale 17.1M Dacogen Royalities -Low end 3.5M Interest Income
45.35M Revenues 2007
We will take a little hit this morning, but institutions will swallow it up. We'll end up around 5.25 today. Like one poster stated it nicely...announcements coming. Mgi stated today that the MDS markets growing 35% per year and Dacogen has better data, better ease of use. The other key point presented today and confirms what Dr. Manuso hinted at, trials are on going in U.S and EU on AML, this leads me to believe that JNJ will file for both MDS and AML around the same time. This makes sense to get the best labeling posibile in EU, takes a little longer but comes out of the blocks fast. MGI has Dacogen projections Greater than 250M...and I believe we see 300M projections by end of the year. Spinout company will be funded with outside money and not by SUPG, this is very important, shareholders will get a piece of new company for nothing. Here's a question for longs, was Orathecin a capsule form drug? They have change the web page and listed it as a phase II drug and now states it's in a capsule form. I wasn't around back then so I'm not sure of how it was administered. I'm probably looking for someone's opinion outside Rory, since after his post I would have to do to much work correcting it. Sorry Rory, just a fact of life. Long term we will move higher.